PulseAugur
EN
LIVE 15:28:20

FDA rejects Chinese cancer drug Ivonescimab, Akeso shares plunge

Akeso's cancer drug, Ivonescimab, has faced a setback as the US Food and Drug Administration (FDA) rejected its application. This led to a significant drop in Akeso's shares, raising concerns about the drug's commercial prospects. Summit Therapeutics, which holds the global rights to Ivonescimab, stated that the drug did not provide sufficient evidence of effectiveness. AI

RANK_REASON Regulatory decision on a specific drug application.

Read on SCMP — Tech →

AI-generated summary · Google Gemini · from 1 sources. How we write summaries →

FDA rejects Chinese cancer drug Ivonescimab, Akeso shares plunge

How we ranked this

Signal score
0 / 100
Composite score across the factors below. Higher = stronger signal that this story matters right now.
Newsworthiness bucket
Tool
Regulatory decision on a specific drug application.
Source corroboration
Single-source cluster
Only one publisher covered this so far. Single-source stories can still rank when the publisher is high-authority, but they lack cross-source corroboration.
Topics
policy, product
Editorial topic classification. Feeds into how the story surfaces on /topic/<slug> hub pages and into the per-entity coverage mix.
AI-industry relevance
Low
Off-topic or adjacent — cluster remains reachable but doesn't surface in AI-industry rankings.
Story freshness
1 days old
Coverage has settled into its steady-state source set.

Full methodology in our editorial standards.

COVERAGE [1]

  1. SCMP — Tech TIER_1 English(EN) · Xinmei Shen ·

    Akeso shares plummet as Chinese firm’s cancer drug ivonescimab faces FDA setback

    Shares in Hong Kong-listed Akeso plunged as much as 31.8 per cent on Monday morning after the US Food and Drug Administration (FDA) rejected its cancer drug application, raising investor worries over the company’s near-term commercial outlook. Ivonescimab, one of the most closely…